Source:http://linkedlifedata.com/resource/pubmed/id/19893592
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-4-19
|
pubmed:abstractText |
Genetic immunotherapy is considered an ideal treatment modality for cancer because of its systemic nature. This study was designed to develop a potent novel genetic immunotherapy by combining conditionally replicating adenovirus (CRAd) and replication-defective adenovirus expressing interferon-beta (ad-IFN-beta). We investigated the efficacy of this therapy in an immunocompetent mouse tumor model. Transduction with CRAd (Delta24RGD) induced cytolysis in a mouse lung cancer cell line (Lewis lung carcinoma (LLC)). Combined transduction of ad-IFN-beta and Delta24RGD in the LLC cells induced a greater and more prolonged production of IFN-beta. Media transfer from the LLC-Delta24RGD-ad-IFN-beta to untransduced LLC cells induced the production of IFN-beta; these results confirmed the replication and release of ad-IFN-beta. LLC cells transduced with ad-IFN-beta and Delta24RGD had decreased tumorigenicity in syngeneic mice. Tumor vaccination with irradiated LLC-ad-IFN-beta-Delta24RGD showed a significant increase in the survival of tumor-bearing syngeneic mice compared with mice with a single transduced LLC vaccination; this was mediated by an enhanced cytotoxic T-lymphocyte response against the LLC cells. The results of this study showed that cotransduced Delta24RGD to ad-IFN-beta aided the replication of ad-IFN-beta in the LLC cells. A high local concentration of IFN-beta and local release of tumor antigen by CRAd induced strong antitumor immunity. This combination strategy might provide a powerful means by which ad-cytokines and CRAd can be combined and other adenoviruses expressing different cytokines might also be used.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1476-5500
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
356-64
|
pubmed:meshHeading |
pubmed-meshheading:19893592-Adenoviridae,
pubmed-meshheading:19893592-Animals,
pubmed-meshheading:19893592-Cell Line, Tumor,
pubmed-meshheading:19893592-Humans,
pubmed-meshheading:19893592-Immunotherapy,
pubmed-meshheading:19893592-Interferon-beta,
pubmed-meshheading:19893592-Lung Neoplasms,
pubmed-meshheading:19893592-Mice,
pubmed-meshheading:19893592-Mice, Inbred C57BL
|
pubmed:year |
2010
|
pubmed:articleTitle |
Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta.
|
pubmed:affiliation |
Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-Do, Republic of Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|